Evotec AG (NASDAQ:EVO – Get Free Report)’s stock price passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $1.60 and traded as low as $1.57. Evotec shares last traded at $1.58, with a volume of 46,513 shares traded.
Wall Street Analysts Forecast Growth
Several research firms have commented on EVO. Weiss Ratings lowered Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. HC Wainwright boosted their price objective on Evotec from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.50.
Get Our Latest Research Report on Evotec
Evotec Trading Down 4.8%
The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.19 and a current ratio of 2.32. The company’s 50-day simple moving average is $1.60 and its 200-day simple moving average is $2.43.
Institutional Investors Weigh In On Evotec
An institutional investor recently raised its stake in Evotec stock. Optiver Holding B.V. increased its stake in shares of Evotec AG (NASDAQ:EVO – Free Report) by 598.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 283,576 shares of the company’s stock after buying an additional 242,973 shares during the quarter. Optiver Holding B.V. owned about 0.08% of Evotec worth $709,000 at the end of the most recent quarter. Institutional investors own 5.81% of the company’s stock.
Evotec Company Profile
Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.
Further Reading
- Five stocks we like better than Evotec
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
